# KSHV-mediated metabolic reprogramming for LANA expression and viral persistency

> **NIH NIH R01** · CLEVELAND CLINIC LERNER COM-CWRU · 2024 · $675,416

## Abstract

Project Summary/Abstract
Metabolic reprograming has been readily recognized as the hallmark of cancer. Specifically, three-
dimensional (3D) cell system is well documented to regain intrinsic metabolic properties and to better
mimic the in vivo situation than two-dimensional (2D) cell system. We have shown that Kaposi’s
sarcoma-associated herpesvirus (KSHV), an etiological agent of Kaposi’s sarcoma (KS) and pleural
effusion lymphoma, specifically alters host spermidine and proline syntheses in a 3D-dependent
manner, contributing to the LANA-mediated latent episomal maintenance for viral persistency and
oncogenesis, which is a crux of this application. As this KSHV-mediated spermidine and proline
biosynthesis reprograming is also shared by most non-viral cancers, this study will contribute to
understanding general cancer metabolic reprograming.

## Key facts

- **NIH application ID:** 10918867
- **Project number:** 1R01AI181758-01A1
- **Recipient organization:** CLEVELAND CLINIC LERNER COM-CWRU
- **Principal Investigator:** Jae U Jung
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $675,416
- **Award type:** 1
- **Project period:** 2024-06-14 → 2029-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10918867

## Citation

> US National Institutes of Health, RePORTER application 10918867, KSHV-mediated metabolic reprogramming for LANA expression and viral persistency (1R01AI181758-01A1). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10918867. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*